CAJ | 학술논문

[目的]探讨NF-κB及IL-1ra在胃癌中的表达及其意义.[方法]通过组织芯片,采用免疫组织化学方法(LSA8法)检测核因子-κB(NF-κB)和抗炎因子白细胞介素-1受体拈抗剂(IL-1ra)在359例胃癌组织中的表达情况.[结果]NF-κB在伴发淋巴结转移、处于TNM Ⅲ+Ⅳ期、组织学分化较低的胃癌患者中的表达水平分别为80.2%、80.0%、79.2%;IL-1ra在原发灶癌直径≤3 cm、早期癌、无淋巴结转移和处于TNM Ⅰ+Ⅱ期的胃癌患者中表达水平分别为61.7%、75.0%、66.4%、61.9%;NF-κB表达阴性的胃癌患者5年生存率高于阳性患者(P=0.036);伴IL-1ra阳性表达的NF-κB阴性表达患者生存率高于其它组别患者(P=0.021).[结论] NF-κB的表达水平可以作为胃癌预后不良的指标;IL-1ra可能是延缓胃癌恶性发展的保护因素,但尚需进一步的研究证实.
[목적]탐토NF-κB급IL-1ra재위암중적표체급기의의.[방법]통과조직심편,채용면역조직화학방법(LSA8법)검측핵인자-κB(NF-κB)화항염인자백세포개소-1수체념항제(IL-1ra)재359례위암조직중적표체정황.[결과]NF-κB재반발림파결전이、처우TNM Ⅲ+Ⅳ기、조직학분화교저적위암환자중적표체수평분별위80.2%、80.0%、79.2%;IL-1ra재원발조암직경≤3 cm、조기암、무림파결전이화처우TNM Ⅰ+Ⅱ기적위암환자중표체수평분별위61.7%、75.0%、66.4%、61.9%;NF-κB표체음성적위암환자5년생존솔고우양성환자(P=0.036);반IL-1ra양성표체적NF-κB음성표체환자생존솔고우기타조별환자(P=0.021).[결론] NF-κB적표체수평가이작위위암예후불량적지표;IL-1ra가능시연완위암악성발전적보호인소,단상수진일보적연구증실.
[Objective] To investigate the expression of NF-κB and IL-lra in gastric cancer, and to explore their correlation with the clinicopathological parameters and prognosis of gastric cancer (GC). [Methods] Expression of NF-κB and IL-1ra was detected by immunohistochemistry in tissue microarry of 359 cases of GC. [Results] The expression rates of NF-κB in the patients with metastasis of lymph node, TNM Ⅲ-Ⅳ stage, and poorly differentiated of histology were 80.2%, 80.0%, and 79.2%, respectively. The expression rates of IL-1ra in the patients with tumor size ≤3 cm, early stage, non-metastasis of lymph node, and TNM Ⅰ-Ⅱ stage were 61.7%, 75.0%, 66.4%, and 61.9%, respectively. The 5-year survival rate of the cases with non-expressed NF-κB was statistically higher than that of the cases with expressed NF-κB(P=0.036). The 5-year survival rate of the patients with negative expression of NF-κB and positive expression of IL-1ra was statistically higher than the others (P=0.021). [Conclusions] NF-κB is the adverse predictors of prognosis of gastric cancer. IL-1ra maybe play a protective role in early gastric cancer stage, but it is necessary to study deeply and get more evidences.